Relugolix in Clinical Practice: The Best Route for All?
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad099 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Lisa M Cordes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Office of Clinical Research, National Institutes of Health, Bethesda, MD, USA.
ORCID-Profile: Lisa M Cordes
Zitieren
APA
Cordes, L. M., Karzai, F., Figg, W. D., & Madan, R. A. (2023). Relugolix in Clinical Practice: The Best Route for All?. The Oncologist. https://doi.org/10.1093/oncolo/oyad099
Vancouver
Cordes LM, Karzai F, Figg WD, Madan RA. Relugolix in Clinical Practice: The Best Route for All?. The Oncologist. 2023. doi:10.1093/oncolo/oyad099
BibTeX
@article{Cordes2023,
author = {Cordes, Lisa M and Karzai, Fatima and Figg, William D and Madan, Ravi A},
title = {Relugolix in Clinical Practice: The Best Route for All?},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad099}
}
EUVIMED